$-0.34 EPS Expected for Crinetics Pharmaceuticals, Inc. (CRNX)

November 11, 2018 - By Harriett Tippett

Analysts expect Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to report $-0.34 EPS on November, 29.After having $-2.41 EPS previously, Crinetics Pharmaceuticals, Inc.’s analysts see -85.89 % EPS growth. The stock decreased 4.69% or $1.32 during the last trading session, reaching $26.84. About 41,610 shares traded. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. The company has market cap of $644.81 million. The Company’s lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. It currently has negative earnings. The firm is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.